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RESULTS: Nearly all the medical innovations studied will result in better health
and longer life, but they will likely increase, not decrease, Medicare spending. One
exception, however, concerns innovations that improve health behavior – e.g.,
treatments that reduce the rate of obesity. Such treatments are likely to be highly
cost-effective – in many cases costing less than $10,000 per life-year saved. Simi-
larly, prevention efforts focused on the most important risk factors for disease,
especially those requiring costly treatments, could be very cost-effective.
CONCLUSIONS: Future Medicare spending through the Baby-Boomer generation
(through 2030) will increase, despite the introduction of medical innovations that
reduce disability and improve outcomes. With the possible - but important - ex-
ception of reducing obesity, Medicare costs will dramatically increase consequent
to the overriding impact of the demographic shifts in the elderly population. Health
policy makers need to incorporate these findings in their health policy initiatives.
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OBJECTIVES: Compare clinical and economic outcomes between post-menopausal
women treated with combined estrogen and progestogen hormone therapy (HT)
within 1 and 1-2 years after diagnosis. METHODS: A retrospective analysis of
women age 45 or older from a large U.S. health plan (April 2002-September 2010)
was conducted. The first HT prescription during the identification period (April
2005-September 2008) was identified as the index date. Patients were selected if
they initiated HT treatment within 2 years of menopause diagnosis, and had 3
years of continuous health plan enrollment before (pre-period) and 2 years after
the index date (post-period). Patients with evidence of post-period pregnancy or
pre-period other HT treatment were excluded. Two cohorts were created based on
HT initiation date (Cohort A: HT initiated within 1 year of diagnosis; Cohort B: 1-2
years after diagnosis). Propensity score matching (PSM) was used to adjust for
baseline differences in age, region, procedure used, comorbidities, and healthcare
utilizations during the pre-period. RESULTS: Among 4268 eligible patients, 69.3%
(N2956) were included in Cohort A and 30.7% (N1871) in Cohort B. After PSM,
1310 patients from each group werematched. Patients prescribed HTwithin 1 year
of menopause diagnosis (Group A) were less likely to have Dual-Energy X-RAY
Absorptiometry (DEXA) scans and osteopenia than patients treated between 1-2
years after menopause diagnosis. In addition, patients with earlier treatment
showed a highermedication possession ratio (MPR) (0.49 vs. 0.46, p0.272). Health-
care costs and utilizations remained similar, except patients with early HT treat-
ment had significantly lower emergency room visit rates (22.9% vs. 26.5%, p0.033)
than patients with late HT treatment. CONCLUSIONS: Patients initiating HTwithin
1 year of menopause diagnosis had fewer comorbidities, directionally higher MPR
but not significant, and lower emergency roomvisit rates thanwomen initiatingHT
between 1-2 years. Other clinical and economic outcomes were similar.
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OBJECTIVES: To identify the potential size of the population in Canada eligible for
infertility screening as a prerequisite to publicly provided funding, and to estimate
the associated costs. METHODS: Using the Canadian Fertility Cost Model frame-
work, an age-specific decision model was developed to estimate the potential size
of theCanadian population eligible for infertility screening. Based on thenumber of
women presenting for annual comprehensive general assessments to their family
physicians, and published age-specific data on the number of women without
children, we estimated the number of Canadian couples eligible for infertility
screening. The total cost of screening was calculated using sex-specific infertility
screening costs. The potential number of live births was also estimated. Sensitivity
analyses were performed. All costs were expressed in 2009 Canadian dollars.
RESULTS: Based on the number of women who undergo an annual physician gen-
eral assessment in Canada, the number of women eligible for infertility screening
was estimated. According to published studies around 50% of infertile women
might seek medical assistance; resulting in approximately 75,000 women aged
30-45 being screened. Assuming 50% of their partners would come for screening,
37,500 males would be screened for infertility. The annual cost of screening has
been estimated at $10.6 million. The resulting number of live births would be
15,800. The proportion of total screening cost attributed to women aged 30-34,
35-39, and 40-45 is 36%, 28% and 36%, respectively. The proportion of total live
births in each age group is 51%, 31% and 18%, respectively. CONCLUSIONS: We
estimated the potential costs of infertility screening, a prerequisite to publicly
provided infertility treatments. Recent studies of selected European countries have
established that public subsidy of IVFmight represent sound fiscal policy, and that
lifetime future tax revenues over an average lifetime of an IVF offspring might
return a positive net value.
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OBJECTIVES: The objective of this study was to investigate the societal costs in
employed patients not able towork due to chronic, long-term, or terminal illness in
Germany and France for potential inclusion in health economic models and hence
influence on decision making.METHODS: Societal costs were investigated by col-
lecting and analysing labour costs, disability benefit and home care benefits in
Germany and France for employed patients. Costs were derived from publicly
available literature or databases. The costs were analysed over 1, 3 and 5 year time
horizons. RESULTS: The analysis showed that public costs could play an important
role in health economic analyses in Germany and France. Productivity loss, disabil-
ity pension and home care benefit during the first year of sickness were on average
€41,224 per employed patient in Germany. It was assumed that patients did not
work during the year at all. The societal costs were €44,952 in France per employed
patient for the first year of sickness. The year 3 per employed patient cumulative
costs in Germany and France were €144,280 and €158,464, respectively. The year 5
per employed patient cumulative costs in Germany and France were €254,205 and
€271,975, respectively. CONCLUSIONS: Societal costs associated with long term
sickness are not insignificant in Germany and France. Although indirect costs are
currently not included as part of reimbursement criteria in Germany and France,
this analysis suggests that the inclusion of these should be considered for standard
health economic analyses where possible. The results are of interest when com-
paring two treatment regimenswhere patients have differing ability to work either
during or after the treatment, or where a majority of patients are employed. The
overall perspective could support decision making beyond assessment of clinical
benefits alone.
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OBJECTIVES: Conventional pricing theory suggests that therapies with additional
benefits over an existing option may garner a higher price to account for this
incremental value/benefit. For reformulated therapies such as extended-release
(ER) products, common patient benefits (e.g. potentially reduced pill burden and
side effects) should provide enough incremental benefit to warrant a price higher
than the immediate-release (IR) formulation of the samemolecule. The objective of
this study is to quantify the intrinsic value of ER formulations by exploring the price
comparison between ER and IR formulations. METHODS: To identify therapies of
interest, a search of the Epocrates drug database was conducted and all therapies
with names indicative of reformulated products were analyzed. The price of each
ERproductwas captured for the first day ofmarket availability and compared to the
branded IR formulation. An analysis of IR generic entry and the time elapsed from
branded IR launch was conducted to determine if these confounding factors ex-
plained the observations. RESULTS: Of the 19 ER products that were analyzed, the
majority (58%) had prices lower than the IR product. Only one-quarter (26%), had
prices higher than the IR product and the remaining products had equivalent
prices. Generic entry did not correlate with the observed price comparisons be-
tween ER and IR formulations. CONCLUSIONS: The percentage price difference
between branded ER and branded IR products did not uncover a standard incre-
mental value that would indicate there is an intrinsic value provided by ER formu-
lations. An analysis of generic entry failed to show that a reduced price reference
may be a factor for products with lower ER prices. It is likely that pricing decisions
for the ER products included unique price sensitivity studies and considered con-
fidential corporate strategy, as is best practice.
INDIVIDUAL’S HEALTH – Patient-Reported Outcomes & Patient Preference
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OBJECTIVES: The purpose of this study was to compare brand and generic medi-
cation adherence in key therapeutic classes, particularly among the generic, and
the non-preferred and preferred brand initiators.METHODS: CVS Caremark phar-
macy claims data (July 1, 2008–July 1, 2011) were analyzed for patients who initi-
ated therapy at retail.We comparedmedication persistence and compliance over a
12-month period in 4 therapeutic classes: angiotensin-converting enzyme inhibi-
tors (ACEIs), angiotensin-II receptor blockers (ARBs), HMG-CoA reductase inhibi-
tors (statins), Biguanides. To qualify for the study, the patients had to be continu-
ously eligible for benefits a total of 18 months, with the additional 6 months to
identify initiators. We compared Medication Possession Ratio (MPR), Medication
Persistence, Proportion of Days Covered (PDC), and the First Fill Persistency (FFPR)
among generic, non-preferred and preferred brand utilizers, on the therapeutic
class level based on GPI-4 codes (ACEIs:3610- ARBs:3615- STATINs:3940- Bigua-
nides:2725). Bi-variate and multi-variate analyses, including linear and logistic re-
gressionwere conducted using SASVersion 9.1with SAS/STAT. RESULTS:A total of
1.1 million patients met inclusion criteria. Compared to brand utilizers, generic
utilizers’ persistency over 12-month was 3% (p0.001) higher; their adjusted 12-
months MPR was 2.65% (p0.001) higher. Generic utilizers were also 17% (p0.001)
more likely to achieve optimal adherence (MPR  80%), and were 18% (p0.001)
more likely to remain on therapy after the first fill. The utilizers of non-preferred
brands had a 1%-5% lower persistence over a 12-month period than did patients on
preferred brandmedications. Finally, thosewho started on a brand and switched to
a generic had 2-5% higher PDC, and 0.6%-2.5% (p0.001) higher 12-months persis-
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tence compared to those who started on a generic and switched to a brand.
CONCLUSIONS: Initiating or switching to generic therapy is associated with signif-
icantly higher compliance and greater therapy persistence compared to initiating
or switching to brand medications.
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OBJECTIVES: Non-adherence to prescription medication is a serious problem. Ac-
curate assessment of adherence is important for improving patients’ health out-
comes and informing decisions made by providers and payers. This study exam-
ined how adherence was defined, measured, and reported in the scientific
literature. METHODS: A systematic review of studies reporting on adherence to
prescription medication for chronic diseases was conducted. Embase® and MED-
LINE® databases were searched. In addition, bibliographies of identified review
papers were assessed for inclusion. Mean overall adherence was estimated using a
random effects model. RESULTS: The review included 266 studies that met pre-
defined inclusion criteria. The definition of non-adherence varied across studies;
73.6% of all studies defined non-adherence as missed/skipped doses only, while
24.3% defined it as discontinuation of therapy only, and 2.1% defined it as either.
Adherencewas recordedusing different tools including claimsdata (55.2%), patient
self-reports (30.5%), pill counts (12.8%), and laboratory tests (1.5%). Furthermore,
included studies used various metrics to assess determinants of adherence, and
some studies used more than one measure. The most commonmetrics were odds
ratios (65.6%), regression coefficients (13.0%), hazard ratios (11.2%), and relative
risks (5.4%). Themeta-analysis showed that themean overall adherence was high-
est in studies that defined non-adherence as missed/skipped doses only (51.7% of
all participants). Mean adherence in studies defining non-adherence as discontin-
uation of therapy only and in studies defining it as missed/skipped doses or dis-
continuation of therapy was 45.4% and 45.0%, respectively. CONCLUSIONS: Incon-
sistencies in the adherence literature pose a challenge to the interpretation,
usefulness, and synthesis of adherence data. There is a clear need formethodolog-
ical standardisation in adherence research and assessment.
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OBJECTIVES: To assess the impact of reducing the frequency of oral therapies from
multiple-dosing schedules to a once-daily (od) dosing schedule on adherence, com-
pliance, and the associated economic impact.METHODS: All relevant studies were
searched using electronic databases (MEDLINE® and Embase®). The studies as-
sessing adherence with od, twice-daily (bid), thrice-daily (tid), and four-times daily
(qid) dosing schedules, and costs associated with optimal/suboptimal adherence
among patients with acute and chronic diseases, were included. There was no
restriction on the treatments assessed other than that they were delivered orally.
Comparisons of effect estimates across studies were pooled and analyzed using a
DerSimonian and Laird random-effects model. RESULTS: Forty-three studies met
the inclusion criteria of the review, ofwhich 33 studies compared once-daily dosing
schedulewithmultiple-dosing schedules. Data on adherence and compliancewere
available for studies in depression, HIV, hypertension, and respiratory tract infec-
tions (RTIs). Among these conditions, the overall results indicated that od schedule
was associated with higher adherence rates [Odds Ratio (OR): 2.34; 95% Confidence
Interval (CI): 1.31, 4.17; p0.004 for od versus bid/tid dosing] and compliance rates
(OR: 5.76; 95% CI: 1.89, 17.57; p0.001 for od versus bid dosing) compared with
multiple-dosing schedules. From a health economic perspective, it was observed
that higher adherence rates with od schedule (relative to multiple-dosing sched-
ules) prescribed in cardiovascular disorders, renal transplant, pain, RTIs, and ul-
cerative colitis were associated with lower costs of healthcare resource utilization.
For example, treatment costs in renal transplant patients demonstrated total, per-
patient cost savings of $9411 over a 5-year time horizonwith od regimen compared
with bid regimen. CONCLUSIONS: The present evidence base suggests that reduc-
ing the dose frequency from multiple dosing to once-daily dosing schedule could
improve adherence and compliance among patients with acute and chronic dis-
eases. Improving adherence was associated with further decreases in health care
costs.
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OBJECTIVES: Non-adherence to treatment predicts poorer health status. Patient
characteristics underlying intentional (INA) and unintentional (UNA) non-adher-
encewere analyzed among eleven costly chronic conditions.METHODS:Data from
U.S. 2011 National Health and Wellness Survey included 30,981 (of 75,000) respon-
dents reporting prescriptions for: asthma, pain, congestive heart failure, COPD,
diabetes, hypertension, depression, bipolar disorder, peripheral vascular disease,
transient ischemic attack, and stroke. Morisky Medication Adherence Scale items
were summed to create INA (“stop taking medicine when feeling better” and
“. . .when feeling worse”) and UNA (“forget to take medicine” and “careless about
taking medicine”) scores ranging from 0adherence to 2high non-adherence.
Across conditions, two logistic regressions predicted INA and UNA (1 vs. 0) from
gender, age, marital status, college education, income, race/ethnicity, exercise12
timesmonthly, alcohol consumption2 timesweekly, cigarette smoking, employ-
ment, health insurance, BMI category, and adjusted Charlson Comorbidity Index
(CCI) score. RESULTS: Adjusting for covariates, significant predictors of INA and
UNA (odds ratios in parentheses for INA and UNA, respectively), were: female
gender (1.32/1.09), younger age (1.04/1.02), education (non-significant [n.s.]/1.13),
employment (n.s./1.13), uninsured status (1.24/n.s.), income $50k (vs. $50k-
$75k: 1.15/n.s.; vs. $75k: 1.20/1.11), Hispanic (1.60/1.20), African American (1.47/
1.21), or other (1.52/1.28) race/ethnicity (vs.White), non-exercise (1.19/1.39), alcohol
consumption (1.12/1.16), smoking (1.25/n.s.), overweight (0.90/1.16), obesity (0.81/
1.37), and high CCI (1.03/1.03); all p.05. CONCLUSIONS: Women, non-Whites,
younger, and poorer respondents, non-exercisers, alcohol consumers, and more
comorbid respondents were at greater risk of non-adherence. Obesity/overweight
predictedhigherUNAbut lower INA risk, perhaps fromobstacles to adherence (e.g.,
complex treatment regimens) but more adherent intentions due to obesity-related
mortality risk. Employment and education were associated only with UNA (per-
haps due to difficulty tracking treatment regimens while engaged in complex oc-
cupations). Smoking and uninsured status were associated only with INA. Simpli-
fied treatments may improve UNA while better access may reduce non-adherence
overall.
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OBJECTIVES: Compliance or adherence to regimens and persistence over time are
common concerns among doctors. The impact of oral once-daily [QD] or twice-
daily [BID dosing regimen on adherence and persistence is unclear, and may po-
tentially affect clinical and economic outcomes. This review aims to identify stud-
ies that identified the impact of QD vs. BID dose regimens of oral treatments on
adherence and persistence in several disease areas that require chronic medica-
tion use.METHODS: Relevant articles were identified through a systematic litera-
ture review from PubMed (2000-2011) using the terms adherence, oral, administra-
tion and dosage, QD, BID, once daily, twice daily, and treatment. Another search
explored the secondary and tertiary references of relevant studies identified
through the bibliographies of articles found in the primary search. RESULTS: Re-
search articles (N16) that met the search criteria comprised the following disease
areas: HIV/AIDS (10 articles), diabetes, ulcerative colitis (2), depression, hyperten-
sion and chronic heart failure. 63% (10/16) of the studies observed improvement on
adherence with the oral QD treatment in comparison to the BID regimen. Of those,
6 were for HIV drugs, 1 for hypertension, 1 for ulcerative colitis, 1 for diabetes and
1 for depression. Articles evaluating drugs for the treatment of ulcerative colitis,
HIV (4) and chronic heart failure found no impact on adherence. Persistence was
measured in 25% (4/16) of the studies, identified the following therapeutic areas:
depression, diabetes and HIV. 50% (2/4) found significantly greater persistence
among patients in the QD regimen versus BID regimens. Studies on HIV medica-
tions did not find any impact on persistence. CONCLUSIONS: Themajority of stud-
ies evaluating adherence of oral QD versus BID treatments for long-term drug
treatments observed improvement of adherence with QD versus BID treatment.
The impact of oral drug dosing frequency on persistence remains unclear and can
vary by therapeutic areas.
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OBJECTIVES: It is important to study the extent to which Medicare Part D’s unique
benefit structure (with a gap in the middle) affects seniors’ adherence to prescrip-
tion medications. Therefore, this study had following objectives: 1) To identify
characteristics of beneficiaries reaching and not reaching the coverage gap, and 2)
To study the impact of a complete gap in coverage on beneficiaries’ adherence to
prescriptionmedications.METHODS: This was a retrospective quasi-experimental
analysis with matched control group using a nationally representative sample of
Part D enrollees of stand-alone prescription drug plans (PDPs) from2008Centers for
Medicare andMedicaid (CMS) Part D and summary datasets. In addition to studying
differences in characteristics of those who did and did not reach the coverage gap
in 2008, adherence to oral medications taken from one or more of the seven pre-
defined therapeutic classes was measured using Medication Possession Ratio
(MPR). Appropriate statistical tests for significance were performed using SAS 9.1.
RESULTS: A quarter of our sample (24.42%) reached the coverage gap in 2008,
mostly by end of September. Of these, 12.10% (2.97% of the total sample) reached
the catastrophic coverage phase. Although the two groups had similar demo-
graphic attributes, beneficiaries reaching the coverage gap had higher prescription
medication use compared to those not reaching the coverage gap (11.25(4.63) vs.
7.39(3.75)). Beneficiaries reaching the gap experienced significantly greater reduc-
tions in adherence (3.00% more for beta-blockers to 9.00% more for oral anti-dia-
betic agents, p-value0.0001), compared to those not reaching the gap. During the
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